TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by WINTON GROUP Ltd

WINTON GROUP Ltd trimmed its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 10.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,436 shares of the biopharmaceutical company’s stock after selling 4,645 shares during the period. WINTON GROUP Ltd’s holdings in TG Therapeutics were worth $1,217,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Blue Trust Inc. boosted its position in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 371 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 1,594 shares during the period. Jones Financial Companies Lllp lifted its holdings in shares of TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 1,737 shares during the last quarter. Synergy Asset Management LLC bought a new stake in TG Therapeutics in the fourth quarter valued at $75,000. Finally, GAMMA Investing LLC lifted its position in TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 2,171 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $40.20 on Friday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market capitalization of $6.31 billion, a price-to-earnings ratio of -401.96 and a beta of 2.30. The company has a 50 day simple moving average of $34.17 and a 200-day simple moving average of $30.18. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. Equities research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 10.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.